Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)
Launched by PHARMACOSMOS UK LTD · Sep 8, 2015
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Intravenous (IV) iron is a well-tolerated and efficacious treatment of iron deficiency anaemia in conditions such as Chronic Kidney Disease (CKD) and Inflammatory Bowel Disease (IBD). Several studies in CKD and IBD patients have shown that IV iron is superior to oral iron, most likely explained by decreased uptake and poor compliance (due to gastrointestinal side-effects) when using oral iron.
The patented Iron Isomaltoside 1000 (Monofer®) has been developed to overcome the current limitations of IV iron drugs with regards to safety and convenience of use. The possibility to administer Mon...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with iron deficiency anaemia as a consequence of CKD or IBD (on the basis of local definition or clinical judgement), treated on the doctor's discretion with Monofer® as standard treatment according to current practice
- Exclusion Criteria:
- • Patients diagnosed with both CKD and IBD
About Pharmacosmos Uk Ltd
Pharmacosmos UK Ltd. is a leading biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with rare and complex diseases. With a strong focus on improving patient outcomes, the company leverages advanced research and development techniques to create high-quality, effective treatments. Pharmacosmos UK Ltd. is committed to fostering partnerships with healthcare professionals, regulatory bodies, and patient advocacy groups to ensure the successful advancement of its clinical programs. The company’s expertise in pharmacology and its robust pipeline underscore its mission to address unmet medical needs and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Exeter, , United Kingdom
Patients applied
Trial Officials
Sylvia Simon, PhD
Study Chair
Pharmacosmos A/S
Jason Moore, BMedSci, BMBS, FRCP
Principal Investigator
Royal Devon and Exeter Hospital NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials